1. Scrip
  2. >>New Products

AstraZeneca, Ionis Win A Key US FDA Approval With Wainua For ATTR Polyneuropathy

Drug Launches In January Under Co-Commercialization Deal

 
• By Mandy Jackson

AstraZeneca adds an important product to its cardiovascular, renal and metabolism (CVRM) portfolio and Ionis gains the first drug it will commercialize as it prepares for its first wholly owned launch.

FDA Approved text on white notepad paper near folders
Wainua is the first patient-administered drug for ATTR-PN • Source: Shutterstock

AstraZeneca PLC and Ionis Pharmaceuticals, Inc. obtained US Food and Drug Administration approval on 21 December for Wainua (eplontersen) in the treatment of adults with hereditary transthyretin mediated amyloidosis (ATTR) with polyneuropathy (ATTR-PN). Phase III data in ATTR cardiomyopathy are not expected until 2025, but AstraZeneca sees Wainua as an important addition to its cardiovascular disease portfolio, while Ionis views the drug as a big first step for its commercial organization.

Key Takeaways

  • The US FDA approved Wainua (eplontersen) for ATTR polyneuropathy, an Ionis antisense oligonucleotide that will be co-commercialized in the US with AstraZeneca.

  • The...

Wainua is a transthyretin (TTR)-directed antisense oligonucleotide (ASO) self-administered as a once-monthly subcutaneous injection, offering a potential advantage relative to Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a TTR-directed small interfering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.